{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-055242","form_type":"8-K","ticker":"QURE","cik":"0001590560","company_name":"uniQure N.V.","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.532048+00:00","generated_at":"2026-05-14T23:22:21.035844+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"uniQure Q1 net loss $53.5M ($0.85/share); AMT-130 UK MAA on track for Q3","bullets":["Net loss of $53.5M vs $43.6M YoY; revenue $3.6M up from $1.6M on license revenue.","Cash $586.6M; runway into H2 2029; R&D down 19% to $29.2M, SG&A up 84% to $20.1M.","FDA Type B meeting scheduled Q2 2026 for AMT-130; UK MAA submission expected Q3 2026.","AMT-260 cohort 2 enrollment on track mid-2026; data from first cohort at June 2026 conference.","AMT-191 dosing paused at mid/high dose due to liver enzyme DLTs; all 11 patients off ERT."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-055242","json":"https://secwatch.observer/filing/0001104659-26-055242.json","markdown":"https://secwatch.observer/filing/0001104659-26-055242.md","text":"https://secwatch.observer/filing/0001104659-26-055242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/0001104659-26-055242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/qure-20260505x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:22:21.035844+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ff12cb5a3472abb9886e5bad94d25b96da6c5cbb","claim":"uniQure N.V. reported financial results for first quarter of 2026.","evidence_excerpt":"uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/0001104659-26-055242-index.htm","confidence":0.95},{"claim_id":"ff12cb5a3472abb9886e5bad94d25b96da6c5cbb","claim":"uniQure N.V. reported financial results for first quarter of 2026.","evidence_excerpt":"Strong balance sheet with $586.6 million in cash, cash equivalents and current investment securities as of March 31, 2026 and runway into the second half of 2029","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/0001104659-26-055242-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001628280-26-039805","ticker":"GTLB","company_name":"Gitlab Inc.","filed_at":"2026-06-02T20:17:31+00:00","headline":"GitLab Q1 revenue $264M (+23% YoY); plans 14% workforce cut, $30-35M charges","event_type":"earnings","sec_items":["2.02","2.05","7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039805","json":"https://secwatch.observer/filing/0001628280-26-039805.json","markdown":"https://secwatch.observer/filing/0001628280-26-039805.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653482/000162828026039805/0001628280-26-039805-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653482/000162828026039805/gtlb-20260601.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/0001104659-26-055242-index.htm","comparable_excerpt":"in such filing. \n\n--- EX-99.1 (EX-99.1) ---\n\nGitLab Reports First Quarter Fiscal Year 2027 Financial Results First Quarter Fiscal Year 2027 Highlights: • Total revenue of $264.2 million, up 23% year-over-year • GAAP operating margin of (6)%; non-GAAP operating margin of 14% • Operating cash flow of $149.2 million and non-GAAP adjusted free cash flow of $146.7","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1653482/000162828026039805/0001628280-26-039805-index.htm"}},{"accession":"0001040130-26-000016","ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2026-06-02T20:15:54+00:00","headline":"PetMed Q4 sales fall 15.6% to $42.8M; FY net loss widens to $57.3M on goodwill impairment","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001040130-26-000016","json":"https://secwatch.observer/filing/0001040130-26-000016.json","markdown":"https://secwatch.observer/filing/0001040130-26-000016.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1040130/000104013026000016/0001040130-26-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1040130/000104013026000016/pets-20260602.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/0001104659-26-055242-index.htm","comparable_excerpt":"Net sales of $179.0 million compared to $227.0 million in the prior year, a decrease of 21.1%, primarily driven by a decline in prescription medication sales. • Net loss of $57.3 million, or $(2.74) per diluted share, compared to a net loss of $6.3 million, or $(0.30) per diluted share in the prior year.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013026000016/0001040130-26-000016-index.htm"}},{"accession":"0001193125-26-253505","ticker":"SPWH","company_name":"SPORTSMAN'S WAREHOUSE HOLDINGS, INC.","filed_at":"2026-06-02T20:10:20+00:00","headline":"Sportsman's Warehouse Q1 net sales up 2.8% to $256.1M; same-store sales +2.1%; net loss $21.8M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-253505","json":"https://secwatch.observer/filing/0001193125-26-253505.json","markdown":"https://secwatch.observer/filing/0001193125-26-253505.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1132105/000119312526253505/0001193125-26-253505-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1132105/000119312526253505/spwh-20260602.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/0001104659-26-055242-index.htm","comparable_excerpt":"and generating positive free cash flow to further strengthen our balance sheet through debt reduction.” For the thirteen weeks ended May 2, 2026: • Net sales increased 2.8% to $256.1 million, compared to $249.1 million in the first quarter of fiscal year 2025. Performance was driven primarily by a 7.4% gain in Hunting and Shooting Sports, led by firearms, ammunition,","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1132105/000119312526253505/0001193125-26-253505-index.htm"}},{"accession":"0001104659-26-069464","ticker":"ULTA","company_name":"Ulta Beauty, Inc.","filed_at":"2026-06-02T20:06:38+00:00","headline":"Ulta Q1 net sales +11.1% to $3.16B, comps +5.3%; FY EPS guidance raised to $28.36-$28.80","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069464","json":"https://secwatch.observer/filing/0001104659-26-069464.json","markdown":"https://secwatch.observer/filing/0001104659-26-069464.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1403568/000110465926069464/0001104659-26-069464-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1403568/000110465926069464/ulta-20260602x8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/0001104659-26-055242-index.htm","comparable_excerpt":"compared to the same period ended May 3, 2025 : ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 13 Weeks Ended ​ ​ May 2, ​ May 3, (Dollars in millions, except per share data) ​ 2026 ​ 2025 Net sales ​ $ 3,163.9 ​ $ 2,848.4 Comparable sales ​ ​ 5.3% ​ ​ 2.9% Gross profit (as a percentage of net sales) ​ ​ 40.1% ​ ​ 39.1% Selling, general and administrative expenses ​ $ 814.7 ​ $ 710.6","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1403568/000110465926069464/0001104659-26-069464-index.htm"}},{"accession":"0001628280-26-039786","ticker":"YEXT","company_name":"Yext, Inc.","filed_at":"2026-06-02T20:05:58+00:00","headline":"Yext Q1 FY27: Adj EBITDA margin 25%, ARR $440.8M; boosts buyback by $100M","event_type":"earnings","sec_items":["2.02","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039786","json":"https://secwatch.observer/filing/0001628280-26-039786.json","markdown":"https://secwatch.observer/filing/0001628280-26-039786.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1614178/000162828026039786/0001628280-26-039786-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1614178/000162828026039786/yext-20260602.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/0001104659-26-055242-index.htm","comparable_excerpt":"Exchange Act, except as expressly set forth by specific reference in such a filing. \n\n--- EX-99.1 (EX-99.1) ---\n\nYext Announces First Quarter Fiscal 2027 Results – Revenue of $107.9 million – Net Income Per Share, basic, of $0.02 or non-GAAP Net Income Per Share of $0.15 – Adjusted EBITDA of $26.9 million, resulting in an Adjusted EBITDA margin of 25% – ARR of","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1614178/000162828026039786/0001628280-26-039786-index.htm"}},{"accession":"0001493152-26-026777","ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2026-06-02T12:40:33+00:00","headline":"INVO Fertility FY2025 revenue $6.84M (+5% YoY); net loss improves to $(5.3)M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026777","json":"https://secwatch.observer/filing/0001493152-26-026777.json","markdown":"https://secwatch.observer/filing/0001493152-26-026777.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226026777/0001493152-26-026777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226026777/form8-k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/0001104659-26-055242-index.htm","comparable_excerpt":"and technologies,\ntoday announced fiscal year 2025 financial results. FY2025\nFinancial Highlights (all metrics compared to FY2024 unless otherwise noted) ● Revenue\n was $6,841,250, an increase of 5% compared to $6,532,000. ● Consolidated\n clinic revenue increased 4% to $6,721,057, compared to $6,450,431. ● Revenue\n from all clinics was $8,021,929, including","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226026777/0001493152-26-026777-index.htm"}},{"accession":"0001493152-26-026770","ticker":"POLA","company_name":"Polar Power, Inc.","filed_at":"2026-06-02T12:30:26+00:00","headline":"Polar Power Q1 net loss narrows 86% to $178K; gross margin expands to 65.7%","event_type":"earnings","sec_items":["2.02","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026770","json":"https://secwatch.observer/filing/0001493152-26-026770.json","markdown":"https://secwatch.observer/filing/0001493152-26-026770.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622345/000149315226026770/0001493152-26-026770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622345/000149315226026770/form8-k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/0001104659-26-055242-index.htm","comparable_excerpt":"Q1 2026 Q1 2025 Y/Y +/(-) Change Net sales $ 1,728 $ 1,723 — Gross profit $ 1,135 $ 320 255 % Gross margin 65.7 % 18.6 % 47.1 pts Total operating expenses $ 1,111 $ 1,421 22 % Income (loss) from operations $ 24 $ (1,101 ) 102 % Net loss $ (178 ) $ (1,265 ) 86 % Net loss per share $ (0.05 ) $ (0.50 ) 90 %","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1622345/000149315226026770/0001493152-26-026770-index.htm"}},{"accession":"0001104659-26-069202","ticker":"CTRN","company_name":"Citi Trends Inc","filed_at":"2026-06-02T10:58:00+00:00","headline":"Citi Trends Q1 sales up 14.4% to $230.9M; adjusted EBITDA doubles to $13.9M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069202","json":"https://secwatch.observer/filing/0001104659-26-069202.json","markdown":"https://secwatch.observer/filing/0001104659-26-069202.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1318484/000110465926069202/0001104659-26-069202-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1318484/000110465926069202/tm2616574d1_8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/0001104659-26-055242-index.htm","comparable_excerpt":"(EXHIBIT 99.1) ---\n\nEX-99.1 2 tm2616574d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CITITRENDS ANNOUNCES FIRST QUARTER\nFISCAL 2026 RESULTS Q1 2026 total sales increased 14.4% to $230.9 million Comparable store sales growth\nof 13.9%; Two-year stack of 23.8% Q1 2026 Net Income of $7.8 million;\nQ1 2026 adjusted EBITDA* of $13.9 million, more than double Q1 2025 results","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1318484/000110465926069202/0001104659-26-069202-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}